FASN and rheumatoid arthritis: To confirm the in vivo therapeutic effect of targeting FASN in RA murine model, we treated collagen‐induced arthritis (CIA) mice with TVB‐3664 (6 mg kg−1, administered intramuscularly three times a week starting at booster immunity) (Figure 6B).